Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Pathology · Atypical Lipomatous Tumor

What Does a Positive MDM2 Test Mean for a Lipoma or Lump?

At a Glance

A positive MDM2 result does not by itself diagnose cancer. MDM2 gene amplification, especially on FISH, supports atypical lipomatous tumor or well-differentiated liposarcoma rather than a typical lipoma, but doctors must interpret it with the biopsy, imaging, and tumor location.

If your pathology report notes a “positive MDM2” result, it means your care team is investigating whether your fatty lump is a standard, benign (non-cancerous) lipoma or a more complex tumor. A true positive result—specifically MDM2 gene amplification—strongly supports a diagnosis of an atypical lipomatous tumor (ALT) or well-differentiated liposarcoma (WDLPS) when combined with other biopsy and imaging findings [1][2].

Many patients wonder: “Does this mean I have cancer?” WDLPS is classified as a low-grade sarcoma (a type of cancer), while ALT is considered a locally aggressive, intermediate tumor [3]. Pure ALTs and WDLPS have little to no risk of spreading (metastasizing) to distant organs [4]. However, they can grow large, press on nearby structures, and grow back (recur) after surgery [5][6].

Not All MDM2 Tests Are the Same

It is critical to know exactly how the laboratory tested for MDM2, as the term “positive” can mean different things depending on the test:

Test Type What It Measures What a Positive Result Means Limitations
IHC (Immunohistochemistry) Looks for the MDM2 protein using a special stain [7]. It is a clue that the tumor might be an ALT/WDLPS. Not definitive. It can be “false positive” or miss tumors. A positive IHC often requires a FISH test to confirm [8][9].
FISH (Fluorescence in situ hybridization) Looks directly at the DNA for extra copies (amplification) of the MDM2 gene [2]. Strongly supports an ALT/WDLPS diagnosis when the cells look abnormal under a microscope. It is a highly preferred confirmatory test, but it still must be interpreted alongside your imaging and physical biopsy [2][10].

Why Doctors Test for MDM2

A standard lipoma is a benign growth of normal fat cells. However, ALTs and WDLPS are closely related tumors that can look almost identical to a benign lipoma under a microscope, especially because they are also made mostly of mature fat cells [11][12].

To tell them apart, pathologists check for a specific genetic copy-number change. In ALTs and WDLPS, the cells typically have extra copies of the MDM2 gene—a state known as “MDM2 amplification” [1][13]. Standard lipomas do not normally have this amplification [2].

The limits of small biopsies: If you only had a small needle biopsy, the sample might miss the specific areas of the tumor that contain abnormal cells (atypia) [10]. Because tumors can be heterogeneous (mixed), doctors use the MDM2 test to help clarify the diagnosis when the physical tissue sample is small or ambiguous [10][14].

ALT vs. WDLPS: What is the Difference?

You might see either “atypical lipomatous tumor” or “well-differentiated liposarcoma” mentioned alongside your MDM2 results. Biologically and genetically, these represent the exact same morphologic entity [15][3].

Doctors use different names based primarily on where the tumor is located and how easily it can be surgically removed:

  • Atypical Lipomatous Tumor (ALT): This term is usually used for tumors in surgically accessible areas, like the arms, legs, or trunk [15][4]. Complete surgical removal is generally easier here, though the tumor can still recur locally.
  • Well-Differentiated Liposarcoma (WDLPS): This term is used when the exact same tumor is located deep inside the body, such as the back of the abdomen (the retroperitoneum) [4][11]. In these deep spaces, the tumor is much harder to remove completely, carrying a higher risk of local recurrence and requiring different clinical management [4].

In rare cases, WDLPS or ALT can develop a “dedifferentiated” component, which behaves more aggressively and changes the risk of spread. This is why thorough pathology review is essential [16].

Putting the Pieces Together

A positive MDM2 test is just one piece of the puzzle. It is never used entirely on its own to make a diagnosis or treatment plan [16]. Your care team will interpret the MDM2 result alongside:

  • The physical traits of the cells: Does the tissue have thick, fibrous bands or unusual-looking cells (atypia) under the microscope? [11][12]
  • Warning Signs (Size and Location): Tumors larger than 5 centimeters or located deep beneath the muscle are warning signs that prompt closer evaluation [17][18]. While size and depth do not definitively diagnose a tumor as ALT/WDLPS, they often trigger the decision to order an MDM2 test or refer you to a specialist.
  • Imaging results: Did your MRI show suggestive features like thick lines (septa) or non-fatty areas inside the lump? [19][20]

Next Steps

Because diagnosing and treating atypical fatty tumors requires specific expertise, you should ideally be evaluated by a specialist team, such as a surgical oncologist or orthopedic oncologist [17][21].

  • If the lump is still present (only a biopsy was done): Do not rush into a routine excision. Discuss removal with a sarcoma specialist, as the surgical approach matters for preventing recurrence [22].
  • If the lump was already removed: Ask your doctor if the surgical margins were clear, whether your slides should be re-reviewed by a soft-tissue pathologist, and what your imaging follow-up schedule should be.

Common questions in this guide

What does a positive MDM2 result mean in a fatty lump?
A positive MDM2 result may support an atypical lipomatous tumor or well-differentiated liposarcoma rather than an ordinary lipoma, especially when testing shows extra copies of the MDM2 gene. The result must be interpreted with the biopsy, imaging, and tumor location.
Does a positive MDM2 test mean that I have cancer?
Not necessarily. A protein stain called IHC can be a clue and may be falsely positive, while MDM2 gene amplification on FISH more strongly supports the diagnosis. Well-differentiated liposarcoma is a low-grade cancer; atypical lipomatous tumor is the term often used for the same tumor in a surgically accessible location.
What is the difference between MDM2 IHC and FISH testing?
IHC uses a stain to look for MDM2 protein in tumor cells. FISH looks directly for extra copies of the MDM2 gene and is commonly used as a confirmatory test when the diagnosis is uncertain. Neither result should be read without the pathology and imaging findings.
Can a regular lipoma have MDM2 amplification?
Standard lipomas do not usually have MDM2 gene amplification. A positive protein stain does not prove amplification and can sometimes be misleading, while a small biopsy can miss abnormal areas. Your care team may use FISH and a specialist pathology review to clarify the result.
Are atypical lipomatous tumor and well-differentiated liposarcoma different tumors?
They are biologically and genetically the same type of tumor. Doctors usually use atypical lipomatous tumor for a tumor in an accessible area such as an arm, leg, or trunk, and well-differentiated liposarcoma for the same tumor in a deep location such as the retroperitoneum. The location affects how completely it can be removed and the risk of local recurrence.
What should I do after a positive MDM2 result?
Ask whether the test was IHC or FISH and whether the result shows MDM2 gene amplification. If the lump remains, discuss removal with a sarcoma specialist rather than rushing into routine excision; if it was removed, ask about clear margins, specialist pathology review, and imaging follow-up.
Can an MDM2-positive tumor spread?
Pure atypical lipomatous tumor and well-differentiated liposarcoma usually have little to no risk of spreading to distant organs, but they can grow locally and recur after surgery. A rare dedifferentiated component can behave more aggressively and change the risk of spread, so complete pathology review matters.

Get notified when new evidence is published on lipoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Detection of MDM2 gene amplification on tissue microarray-based Fluorescence In-Situ Hybridization (FISH) in well-differentiated and dedifferentiated liposarcomas, displaying a wide morphological spectrum: A validation study at a tertiary cancer referral centre.

    Rekhi B, Karnik N, Agrawal R, et al.

    Indian journal of pathology & microbiology 2022; (65(1)):65-75 doi:10.4103/IJPM.IJPM_1238_20.

    PMID: 35074968
  2. 2

    MDM2 RNA In Situ Hybridization for the Diagnosis of Atypical Lipomatous Tumor: A Study Evaluating DNA, RNA, and Protein Expression.

    Kulkarni AS, Wojcik JB, Chougule A, et al.

    The American journal of surgical pathology 2019; (43(4)):446-454 doi:10.1097/PAS.0000000000001199.

    PMID: 30520819
  3. 3

    Differentiation of lipoma and atypical lipomatous tumor by a scoring system: implication of increased vascularity on pathogenesis of liposarcoma.

    Nagano S, Yokouchi M, Setoguchi T, et al.

    BMC musculoskeletal disorders 2015; (16()):36 doi:10.1186/s12891-015-0491-8.

    PMID: 25879189
  4. 4

    Atypical Lipomatous Tumors: Does Our Inconsistent Terminology Have Patient Repercussions? Results of a Meta-Analysis.

    Fourman MS, van Eck CF, Weiss KR, et al.

    American journal of clinical oncology 2019; (42(5)):487-492 doi:10.1097/COC.0000000000000540.

    PMID: 30932920
  5. 5

    Surgical management of truncal and extremities atypical lipomatous tumors/well-differentiated liposarcoma: A systematic review of the literature.

    Choi KY, Jost E, Mack L, Bouchard-Fortier A

    American journal of surgery 2020; (219(5)):823-827 doi:10.1016/j.amjsurg.2020.01.046.

    PMID: 32029218
  6. 6

    Atypical Lipomatous Tumors of the Extremities and Trunk Wall-The First Case Series of Chinese Population With 45 Cases.

    Chang DH, Ma H, Liao WC, et al.

    Annals of plastic surgery 2016; (76 Suppl 1()):S8-12 doi:10.1097/SAP.0000000000000702.

    PMID: 26808737
  7. 7

    Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case-control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization.

    Nomura K, Tomita M, Kuroda K, et al.

    BMC cancer 2024; (24(1)):1437 doi:10.1186/s12885-024-13215-4.

    PMID: 39574032
  8. 8

    Histopathological Correlation of Chromosome 12 Polysomy by Fluorescence in Situ Hybridization in Adipocytic Neoplasms.

    Wilcock DM, McMurtry V, Coleman JF, et al.

    International journal of surgical pathology 2022; (30(7)):734-742 doi:10.1177/10668969221085289.

    PMID: 35261272
  9. 9

    MDM2 and CDK4 Immunohistochemistry: Should It Be Used in Problematic Differentiated Lipomatous Tumors?: A New Perspective.

    Clay MR, Martinez AP, Weiss SW, Edgar MA

    The American journal of surgical pathology 2016; (40(12)):1647-1652 doi:10.1097/PAS.0000000000000713.

    PMID: 27508976
  10. 10

    Atypical lipomatous tumor/well differentiated liposarcoma and related mimics with updates. When is molecular testing most cost-effective, necessary, and indicated?

    Kilpatrick SE

    Human pathology 2024; (147()):82-91 doi:10.1016/j.humpath.2023.12.005.

    PMID: 38135062
  11. 11

    Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review.

    Thway K

    Seminars in diagnostic pathology 2019; (36(2)):112-121 doi:10.1053/j.semdp.2019.02.006.

    PMID: 30852045
  12. 12

    Lessons learnt from MDM2 fluorescence in-situ hybridisation analysis of 439 mature lipomatous lesions with an emphasis on atypical lipomatous tumour/well-differentiated liposarcoma lacking cytological atypia.

    Vargas AC, Joy C, Cheah AL, et al.

    Histopathology 2022; (80(2)):369-380 doi:10.1111/his.14558.

    PMID: 34523152
  13. 13

    p16 Expression in Fat Necrosis: A Potential Diagnostic Pitfall in the Evaluation of Differentiated Adipocytic Neoplasms.

    Ng W, Messiou C, Smith M, Thway K

    International journal of surgical pathology 2015; (23(7)):544-8 doi:10.1177/1066896915595465.

    PMID: 26173427
  14. 14

    Routine MDM2 FISH Testing and Preoperative Biopsy Reduces Recurrence Rate of Atypical Lipomatous Tumours.

    Ching SOH, Leung ASM, Yau RCH, et al.

    Journal of surgical oncology 2026; (134(6)):814-821 doi:10.1002/jso.70349.

    PMID: 42522378
  15. 15

    Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma of the Salivary Gland and Its Diagnostic Challenges: A Case Report and Literature Review.

    Khan B, Khan J, Al Hmada Y, Abbas S

    International journal of surgical pathology 2026; 10668969261458405 doi:10.1177/10668969261458405.

    PMID: 42484517
  16. 16

    MDM2 gene amplification in surgical pathology: biology, diagnostic utility, and clinical relevance in the modern era.

    Al-Zaidi RS, Baraban E, Gross JM

    Seminars in diagnostic pathology 2026; (43(4)):151029 doi:10.1016/j.semdp.2026.151029.

    PMID: 42284815
  17. 17

    Management of adipose tumors in the limbs.

    Le Nail LR, Crenn V, Rosset P, Ropars M

    Orthopaedics & traumatology, surgery & research : OTSR 2022; (108(1S)):103162 doi:10.1016/j.otsr.2021.103162.

    PMID: 34863958
  18. 18

    Differentiating atypical lipomatous tumors from lipomas with magnetic resonance imaging: a comparison with MDM2 gene amplification status.

    Knebel C, Neumann J, Schwaiger BJ, et al.

    BMC cancer 2019; (19(1)):309 doi:10.1186/s12885-019-5524-5.

    PMID: 30943944
  19. 19

    A scoring system combining clinical, radiological, and histopathological examinations for differential diagnosis between lipoma and atypical lipomatous tumor/well-differentiated liposarcoma.

    Asano Y, Miwa S, Yamamoto N, et al.

    Scientific reports 2022; (12(1)):237 doi:10.1038/s41598-021-04004-1.

    PMID: 34997060
  20. 20

    Use of radiologic imaging to differentiate lipoma from atypical lipomatous tumor/well-differentiated liposarcoma: Systematic review.

    Muhib M, Abidi SLF, Ahmed U, et al.

    SAGE open medicine 2024; (12()):20503121241293496 doi:10.1177/20503121241293496.

    PMID: 39526094
  21. 21

    Revisiting a soft tissue pathology heresy: a clinicopathological study of 17 retroperitoneal lipomas (with comparison to well-differentiated liposarcoma).

    Wong DD, Namjoshi A, Coveney A, et al.

    Pathology 2025; (57(4)):450-454 doi:10.1016/j.pathol.2024.10.011.

    PMID: 39984418
  22. 22

    Diagnostic performance of MRI and histology in assessment of deep lipomatous tumours.

    Cairncross L, Snow HA, Strauss DC, et al.

    The British journal of surgery 2019; (106(13)):1794-1799 doi:10.1002/bjs.11309.

    PMID: 31502664

This page explains what a positive MDM2 result may mean in a lipoma or fatty lump for informational purposes only; it does not constitute medical advice. Your pathologist and sarcoma specialist should interpret the result with your biopsy, imaging, and clinical findings.